Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance Against Line Probe Assays and Phenotyping
Overview
Authors
Affiliations
Use of whole-genome sequencing (WGS) for routine mycobacterial species identification and drug susceptibility testing (DST) is becoming a reality. We compared the performances of WGS and standard laboratory workflows prospectively, by parallel processing at a major mycobacterial reference service over the course of 1 year, for species identification, first-line resistance prediction, and turnaround time. Among 2,039 isolates with line probe assay results for species identification, 74 (3.6%) failed sequencing or WGS species identification. Excluding these isolates, clinically important species were identified for 1,902 isolates, of which 1,825 (96.0%) were identified as the same species by WGS and the line probe assay. A total of 2,157 line probe test results for detection of resistance to the first-line drugs isoniazid and rifampin were available for 728 complex isolates. Excluding 216 (10.0%) cases where there were insufficient sequencing data for WGS to make a prediction, overall concordance was 99.3% (95% confidence interval [CI], 98.9 to 99.6%), sensitivity was 97.6% (91.7 to 99.7%), and specificity was 99.5% (99.0 to 99.7%). A total of 2,982 phenotypic DST results were available for 777 complex isolates. Of these, 356 (11.9%) had no WGS comparator due to insufficient sequencing data, and in 154 (5.2%) cases the WGS prediction was indeterminate due to discovery of novel, previously uncharacterized mutations. Excluding these data, overall concordance was 99.2% (98.7 to 99.5%), sensitivity was 94.2% (88.4 to 97.6%), and specificity was 99.4% (99.0 to 99.7%). Median processing times for the routine laboratory tests versus WGS were similar overall, i.e., 20 days (interquartile range [IQR], 15 to 31 days) and 21 days (15 to 29 days), respectively ( = 0.41). In conclusion, WGS predicts species and drug susceptibility with great accuracy, but work is needed to increase the proportion of predictions made.
Dhasmana D, Whitaker P, van der Laan R, Frost F NPJ Prim Care Respir Med. 2024; 34(1):45.
PMID: 39709516 PMC: 11663218. DOI: 10.1038/s41533-024-00403-9.
PLoS Comput Biol. 2024; 20(8):e1012260.
PMID: 39102420 PMC: 11326700. DOI: 10.1371/journal.pcbi.1012260.
Zhang L, Lin T, Liu W, Ling F ACS Environ Au. 2024; 4(3):127-141.
PMID: 38765059 PMC: 11100324. DOI: 10.1021/acsenvironau.3c00074.
Kiselinova M, Naesens L, Huis In t Veld D, Boelens J, Van Braeckel E, Vande Weygaerde Y Pathogens. 2024; 13(1).
PMID: 38276158 PMC: 10819148. DOI: 10.3390/pathogens13010012.
Davies T, Swann J, Sheppard A, Pickford H, Lipworth S, AbuOun M Microb Genom. 2023; 9(12).
PMID: 38100178 PMC: 10763500. DOI: 10.1099/mgen.0.001151.